Cerebral oedema as a possible complication of treatment with imatinib

Lancet

Volumn 359, Issue 9319, 2002, Pages 1751-1752

  Ebnoether M ^a   Stentoft, J ^b   Ford, J ^c   Buhl, L ^b   Gratwohl, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HYDROXYUREA; IMATINIB;

ADULT; AGED; ARTICLE; BRAIN EDEMA; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037129739     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08616-6     Document Type: Article

References (5)

1. The molecular biology of chronic myeloid leukemia
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
3. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome
4. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
5. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling